IL1B and heart failure: In addition to the early phase data supporting the role of IL1β inhibition in solid tumor malignancies, the phase III CANTOS trial randomised 10,061 patients with heart failure to the IL1β inhibitor canakinumab (Ilaris®) or placebo (Ridker et al., 2017), and found a greater than 50% reduction in the risk of death from all cancers.